>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:
  • N/A
M&A news:
  • RIO +0.6% (Rio Tinto confirms Yancoal as the preferred buyer of its thermal coal assets in Australia)
Other news:
  • SRNE +15.9% (successful Phase 1 / 2 pharmacokinetic bridging trial of the lead product SP-102)
  • STOR +8.9% (announces that Berkshire Hathaway (BRK.A/B) has invested $377 mlnin the company, representing 9.8% of total shares outstanding)
  • CBIO +4.9% (positive preclinical results of CB 2679d/ISU304)
  • AVEO +4.8% (continued strength)
  • TGTX +3.7% (recaps preliminary results from its ongoing Phase 2 study of TG-1101)
  • CNAT +3.7% (confirms being granted Orphan Drug Designation by the FDA for IDN-7314)
  • P +2.5% (CEO Tim Westergren plans to leave the company, according to ReCode)
  • AMD +1.3% (continued strength following last weeks 25% rise)
  • MOMO +1.1% (continued strength)
Analyst comments:
  • PTLA +4.1% (target raised to $70 from $50 at Morgan Stanley)
  • MU +2.1% (target raised to $40 from $32.50 at Wells Fargo)
  • CS +1.6% (resumed with a Overweight at JP Morgan)
  • COH +1.6% (upgraded to Buy from Neutral at Buckingham Research)
  • UBS +1.2% (upgraded to Overweight from Neutral at JP Morgan)
  • COST +1.1% (upgraded to Outperform from Mkt Perform at Raymond James)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • N/A
Select metals/mining stocks trading lower:
  • SSRI -3.6%, GFI -3.6%, GOLD -1.9%, NEM -1.9%, RGLD -1%
Other news:
  • NEOT -69.8% (announces top-line results for Phase 2 proof-of-concept study of LIPO-202)
  • MTNB -48.7% (topline data from its Phase 2 safety, tolerability and efficacy study of MAT2203 did not meet primary endpoint)
  • DRYS -9.8% (provides Kalani Investments update)
  • AMAG -7.4% (FDA Filing Acceptance of Supplemental NDA for Makena subcutaneous auto-injector; reaffirms 2017 financial guidance)
  • AGIO -6.9% (reports new data from DRIVE PK study; Program on track to enter global pivotal development in 1H18)
  • SGEN -6.7% (Seattle Genetics and Takeda Pharmaceutical (TKPYY) announce that the Phase 3 ECHELON-1 clinical trial met its primary endpoint)
  • DMRC -3.4% (to sell 500,000 common shares in a registered direct offering to a certain investor at a price of $35.55 per share)
  • BBRY -1.3% (continued weakness)
Analyst comments:
  • SSYS -2.8% (downgraded to Sell from Neutral at Goldman)
  • INTU -0.9% (downgraded to Neutral from Buy at Citigroup)

>>>Schnitzer Steel reports EPS in-line with upside preannouncement

Schnitzer Steel reports EPS in-line with upside preannouncement (21.60)
  • Reports Q3 (May) earnings of $0.56 per share, excluding non-recurring items, in-line with the single analyst estimate of $0.56; revenues rose 35.5% year/year to $477 mln.
  • Preannonced Q3 adj. EPS $0.52-0.56 vs. $0.42 consensus on June 15.
  • "Our third quarter results benefited from our continued focus on profitable growth. In both our Auto and Metals Recycling and our Steel Manufacturing Businesses, higher volumes and operating leverage from our multi-year productivity initiatives drove increased operating income," commented Tamara Lundgren, President and Chief Executive Officer. "Through the first nine months of this year, we have achieved our best earnings performance since fiscal 2012." "Our balance sheet continued to strengthen as we generated strong operating cash flow, driven primarily by higher profitability and also by lower working capital as compared to the second quarter. This enabled us to reduce debt while continuing to invest in our operations and to return capital to our shareholders."

NYT - Deal Book - Third Point, a Hedge Fund, Sets Its Activist Sights on Nestlé

Third Point, a Hedge Fund, Sets Its Activist Sights on Nestlé

LONDON — Over the past two decades, the hedge fund mogul Daniel S. Loeb has established himself as one of the biggest activist investors around. Now, he has set his sights on one of Europe’s largest corporate citizens: Nestlé, the global food giant.

In a letter to investors sent on Sunday, his Third Point hedge fund argued that Nestlé, a Swiss conglomerate whose wares range from candy to baby food to pet food, should sell its stake in L’Oréal and sell off nonessential operations as part of a broad shake-up.

It is the latest ambitious move by an activist investor to rattle the leaders of the corporate world. Flush with cash, these funds have taken stakes in ever-bigger companies, hoping to goad them into selling themselves or breaking themselves up to improve their stock prices.

Jana Partners, for instance, prodded change at Whole Foods Market. This month, that grocery store chain announced that it was selling itself to Amazon for $13.4 billion. And Trian Fund Management took a $3.5 billion stake in Procter & Gamble, a consumer products behemoth that has sought a way to improve stagnant sales.

Third Point disclosed that it owned about 40 million shares in Nestlé, a stake that amounts to about $3.5 billion in stock. That would make the hedge fund the Swiss company’s sixth-largest shareholder, according to Standard & Poor’s Global Market Intelligence.

Behind Third Point’s investment in Nestlé is a conviction that the company must do more to reshape its product portfolio and adapt to changing consumer tastes and competition from smaller, local brands. The hedge fund argued that the company’s earnings per share figure had not meaningfully improved over the last five years.

Shares in Nestlé have risen nearly 15 percent over the last 12 months, trailing those of its fellow consumer conglomerate Unilever but outpacing those of other food companies like Mondelez and Kraft Heinz.

“Third Point invested in Nestlé because we recognized a familiar set of conditions that make it ripe for improvement and change,” the hedge fund wrote in its investor letter. “It is rare to find a business of Nestlé’s quality with so many avenues for improvement.”

A representative for Nestlé was not available for comment.

Third Point said it was encouraged by Nestlé’s announcement this month that it was weighing the sale of its American candy business, which produces stalwart sweets like Butterfingers and Gobstoppers.

But the hedge fund argued that Nestlé should also sell its 23 percent stake in L’Oréal, the big cosmetics maker whose products include its namesake beauty brand and luxury products like Kiehl’s. The fund argued that the holding was nonstrategic and could be sold off without incurring huge taxes.

In a change from previous investments, in which Mr. Loeb was known for his venomous attacks on the chief executives of the targeted companies, Third Point has praised Nestlé’s leader, Ulf Mark Schneider. The hedge fund pointed positively to his earlier tenure at the German medical supply company Fresenius. But to succeed at Nestlé, the hedge fund argued, he needs to present a bold strategy that would overhaul the food giant’s performance.

Mr. Loeb may not have read Nestle’s news releases over the last few weeks. In May, the company announced that it had teamed up with Amazon to offer a cooking companion with step-by-step recipe instructions, visual aids, skill demonstrations and other content to help consumers prepare meals.

The same month, it announced it was retooling its Maggi line to eliminate ingredients consumers do not like and add vegetables, grains and other more nutritional items.

The company also announced this month that it was the lead investor in a $77 million investment in Freshly, a subscription meal service.

In addition, the company has worked over the last several years to strip preservatives and other ingredients from its ice creams and decidedly improve its vast frozen foods portfolio.

Third Point said it had hired Jan Bennink, a former executive chairman of Sara Lee, to advise the hedge fund on its investment.

>>> US Early premarket gappers

Early premarket gappers
Gapping up:
  • MARA +13.4%, AVEO +5.6%, PTLA +3.1%, TRVG +2.6%, MU +1.8%,ATVI +1.6%, AMD +1.1%, MOMO +0.9%, VOD +0.9%, NVDA +0.9%, JD+0.8%, BIDU +0.8%, SHPG +0.7%, COST +0.7%, TSLA +0.7%
Gapping down:
  • SSRI -3.3%, GOLD -1.5%, OPK -1.1%, OCLR -1.1%, RGLD -1%, REGN -0.7%

>>> Goldman Adds Twelve Stocks to Rebranded `Sustain' Focus List

Goldman Adds Twelve Stocks to Rebranded `Sustain' Focus List

Goldman equity research rebrands its "GS Sustain Focus List" as the "GS Sustain 50," recommending fifty stocks to adapt to a more challenging quality environment.
  • Sees need for increased emphasis on growth and return momentum to enhance outperformance
  • Says previous list didn’t deliberately manage skews, "which resulted in significant unintended weightings at times, both at the region and sector level"
  • 12 additions to the list: Albemarle, AmorePacific, Celanese, Cerner, Disco, Enterprise Product Partners, Equinix, Marriott, Murata Manufacturing, Nitori, Power Grid, Telekomunikasi Indonesia
  • 13 removals: AIA Group, BHP Billiton, Bristol-Myers Squibb, Coloplast, Delphi Automotive, Dollar Tree Stores, InterContinental Hotels Group, Novo Nordisk, Novozymes, Richemont, Shire, Tiffany & Co., TSMC

>>> Lannett received FDA approval for its ANDA for Hydrocodone Bitartrate and Ac

Lannett received FDA approval for its ANDA for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg, the therapeutic equivalent to the reference listed drug, Norco Tablets, of Allergan (19.95)
Arthur Bedrosian, chief executive officer of Lannett stated, "We plan to launch all of our recently approved products in our new fiscal year, which begins next week. With a number of drug applications pending at the FDA, both our own filings and those of our alliance partners, we believe additional approvals are forthcoming."

FT : Moody’s upgrade sends Greek bonds to strongest level since crisis

Greece might have a long way to go to recover from its devastating crisis, but things are finally starting to look up after the country’s creditors agreed a deal to unlock the next stage of its bailout programme and help it avoid a default.
Prices for the government’s few publicly-traded bonds hit their highest level in more than seven years on Monday morning, after the bailout agreement prompted Moody’s to upgrade the government’s credit rating and signal further positivity ahead.
Yields on the government’s benchmark 10-year debt, which fall when prices rise, fell 7 basis points (0.07 percentage points) on Monday morning to 5.2550 per cent, their lowest level since 2009.
The government’s shorter-term debt rallied even further, with yields on its two-year bonds falling 14.3bps to 3.597 per cent.
The vast majority of Greek government debt is held by creditors in the EU and IMF, but the yields are still a useful indicator of investor sentiment on the country’s economy.
Moody’s upgraded the government’s sovereign credit rating to Caa2 with a positive outlook at the end of last week. This month’s agreement with its major creditors may have only patched over some of the disagreements surrounding debt relief, but the ratings agency said the agreement sends “a positive signal regarding the future path of the programme”.
Moody’s was also encouraged by the Syriza government’s stronger fiscal position and “tentative” signs that the economy has stabilised after shrinking more than 27 per cent. Moody’s said it expects Greece’s economy to grow for at least the next two years, while the government’s debt to GDP ratio will stabilise at 179 per cent in 2017 before starting to fall next year.
Still, before anyone gets too carried away, it did warn that the country is still far from healthy:
Greece’s economic, fiscal and political risks remain very elevated. Negative scenarios – in particular linked to political events and delays in implementing the agreed measures – are entirely plausible. They are the key reason why Moody’s considers that a Caa2 rating remains appropriate, at least until the means and extent of the promised medium-term debt relief has been fully clarified, the conditions for any such debt relief are clear and a longer and stronger track record of parliamentary and electoral acquiescence in reform implementation has been established.

(Natixis) M&A Radar - full note attached in French

Cibles potentielles : SPIE (Acheter), ADP (Acheter, Valeur Recommandée), Inside Secure (Acheter), FNAC DARTY (Acheter, Valeur Recommandée), AccorHotels (Acheter), Schoeller Bleckmann (Acheter, Valeur Recommandée), ASMi (Acheter), SFL (=), Groupe Eurotunnel (Neutre), Wolseley (Neutre), Danone (Acheter, Valeur Recommandée), Innogy (non suivie), Albioma (+).

Acquéreurs potentiels : Vinci (Acheter), Eiffage (Acheter), Atlantia (Neutre) Alstom (Acheter), Rentokil (non suivie), Carlsberg (Acheter), AccorHotels (Acheter), Sodexo (Acheter, Valeur Recommandée), Carrefour (Acheter), Compass Group (Neutre), Engie (Neutre), Klépierre (Acheter), Legrand (Alléger), Siemens (Neutre), Philips (Acheter), ABB (Neutre), CRH (Acheter), LafargeHolcim (Alléger), Applied Materials (non suivie), Large Caps pharmaceutiques européens, Atos (Acheter), Capgemini (Neutre), Technicolor (Acheter), Amadeus (Neutre), Teleperformance (Acheter, Valeur Recommandée).

Full note attached in French